Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth

Biosimilar drugmaker Alvotech (ALVO) reported a significant 200%+ year-over-year surge in product revenues to nearly $205 million in H1 2025, primarily driven by its partnership-based commercial model for immunology biosimilars like Simlandi and Selarsdi, marketed by Teva and Stada. This strategy, which includes upfront and milestone payments, underpins the company's reaffirmed full-year 2025 revenue guidance of $600-$700 million and is facilitating diversification into ophthalmology with Mynzepli and pipeline expansion into neurology and oncology through new alliances. While shares have underperformed year-to-date and trade at a premium P/S ratio of 3.23x, Alvotech has seen significant improvements in its 2025 and 2026 EPS estimates.

Analysis

Alvotech (ALVO) is demonstrating robust top-line momentum driven by its capital-light, partnership-based commercial model. Product revenues surged over 200% year-over-year in the first half of 2025 to nearly $205 million, fueled by the successful marketing of its immunology biosimilars, Simlandi and Selarsdi, by partners Teva and Stada. This performance supports the company's reaffirmed full-year 2025 revenue guidance of $600-$700 million. The strategy not only facilitates rapid market entry but also strengthens Alvotech's financial position through a dual income stream of product sales and milestone payments, which is critical in the capital-intensive biosimilar industry. Furthermore, the company is strategically diversifying its pipeline beyond immunology, entering the ophthalmology market with its recently EU-approved Eylea biosimilar, Mynzepli, and expanding into neurology and oncology. Despite this strong fundamental execution and significant upward revisions in 2025 and 2026 EPS estimates, Alvotech's shares have underperformed the industry year-to-date and trade at a premium price-to-sales ratio of 3.23x, compared to the industry average of 2.12x.

Key Decisions for Investors

• Investors should consider the significant upward revisions in 2025 and 2026 EPS estimates as a primary indicator of growing confidence in Alvotech's earnings power, which may not yet be reflected in its year-to-date stock performance.
• The premium valuation, with a P/S ratio of 3.23x versus the industry's 2.12x, requires investors to weigh the company's high-growth trajectory against the risk of multiple contraction, making it crucial to monitor execution on its reaffirmed $600-$700 million revenue guidance.
• Monitor the commercial progress of new market entries, particularly the ophthalmology biosimilar Mynzepli in the EU and pipeline developments in oncology and neurology, as these are key catalysts for justifying the current valuation and sustaining long-term growth.
• Given the negative sentiment signal for originator companies like AbbVie (ABBV) and Johnson & Johnson (JNJ), investors holding positions in these names should view the success of Alvotech's biosimilars as a direct competitive headwind.